Jaypirca: what changed in the evidence · Jaypirca · Dec 2025

What did the CLL/SLL confirmatory trial show beyond progression-free survival?

Similar response rates at the primary analysis (31.1% and 29.4%), a 6.6-month median follow-up, and, at 19.8 months, an overall-survival hazard ratio of 1.09 after 50 of 119 comparator patients had crossed over to pirtobrutinib.

EphemerisX Research · Published October 8, 2026 · 3 source documents · 1 min read

Short answer

At the primary analysis, after a median follow-up of 6.6 months, response rates were similar in the two arms (31.1% and 29.4%). At an updated analysis after 19.8 months, 32% of patients on pirtobrutinib and 27% on the comparator had died, an unadjusted overall-survival hazard ratio of 1.09 (95% CI 0.68 to 1.75); 50 of the 119 comparator patients had crossed over to pirtobrutinib.

What the evidence shows

The trial randomized 238 patients who were previously treated for CLL/SLL, including a covalent BTK inhibitor FDA · Dec 3, 2025. Follow-up: The median duration of follow up at the primary analysis was 6.6 months FDA · Oct 2, 2026 · p. 20. Responses: At the primary analysis for PFS the objective response rate (ORR) as assessed by IRC using 2018 iwCLL criteria, was 31.1% (95% CI 23.0, 40.2) in the JAYPIRCA arm and 29.4% (95% CI 21.4, 38.5) in the investigator choice arm FDA · Oct 2, 2026 · p. 21.

Survival: At an updated analysis with a median follow-up time of 19.8 months, 38 patients (32%) in the JAYPIRCA arm and 32 patients (27%) in the investigator’s choice arm died. The unadjusted HR for overall survival (OS) was 1.09 (95% CI: 0.68, 1.75) FDA · Oct 2, 2026 · p. 21. At that analysis The ORR was 48.7% (95% CI 39.5, 58.1) in the JAYPIRCA arm and 38.7% (95% CI 29.9, 48.0) in the investigator choice arm FDA · Oct 2, 2026 · p. 21.

Crossover: Crossover to JAYPIRCA monotherapy was permitted for patients in the investigator’s choice arm after confirmed disease progression FDA · Dec 3, 2025; Of the 119 patients in the investigator’s choice arm, 50 crossed over to receive JAYPIRCA therapy FDA · Dec 3, 2025.

The FDA's requirement had named overall survival as a secondary endpoint: with secondary endpoints that include response rate and overall survival FDA · Dec 1, 2023 · p. 2. The FDA has posted a review only for the January 2023 approval; for the later decisions the record is the letters, the labels and the FDA's announcements. How this compares with the 2026 trial: How do Jaypirca's four FDA decisions compare, side by side?

Follow the thread

Did the traditional approval cover the same patients as the accelerated approval?238 randomized patients
How do Jaypirca's four FDA decisions compare, side by side?Investigator's choice IR or BR

The documents, by date

The passages quoted

FDA approval letter, December 1, 2023 · page 2

4557-1 Complete a randomized trial in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Patients should be randomized to receive pirtobrutinib or an investigator’s choice arm of idelalisib plus rituximab or bendamustine plus rituximab. The primary endpoint should be progression-free survival, with secondary endpoints that include response rate and overall survival.

Open at the source →

FDA announcement, December 3, 2025

Of the 119 patients in the investigator’s choice arm, 50 crossed over to receive JAYPIRCA therapy. At an updated analysis with a median follow-up time of 19.8 months, the HR for overall survival (OS) was 1.09 (95% CI: 0.68, 1.75).

Open at the source →

FDA announcement, December 3, 2025

Patients were randomized (1:1) to receive either pirtobrutinib or investigator’s choice of idelalisib plus a rituximab product (IR) or bendamustine plus a rituximab product (BR). Crossover to JAYPIRCA monotherapy was permitted for patients in the investigator’s choice arm after confirmed disease progression.

Open at the source →

FDA announcement, December 3, 2025

Efficacy was evaluated in BRUIN-CLL-321 (NCT 04666038), a randomized, open-label, active-controlled trial. The trial randomized 238 patients who were previously treated for CLL/SLL, including a covalent BTK inhibitor. Patients previously treated with a non-covalent BTK inhibitor were not permitted.

Open at the source →

FDA-approved label, October 2, 2026 · page 20

Efficacy was established based on progression-free survival (PFS), as assessed by an Independent Review Committee (IRC) using 2018 iwCLL criteria. The median duration of follow up at the primary analysis was 6.6 months.

Open at the source →

FDA-approved label, October 2, 2026 · page 21

At the primary analysis for PFS the objective response rate (ORR) as assessed by IRC using 2018 iwCLL criteria, was 31.1% (95% CI 23.0, 40.2) in the JAYPIRCA arm and 29.4% (95% CI 21.4, 38.5) in the investigator choice arm.

Open at the source →

FDA-approved label, October 2, 2026 · page 21

At an updated analysis with a median follow-up time of 19.8 months, 38 patients (32%) in the JAYPIRCA arm and 32 patients (27%) in the investigator’s choice arm died. The unadjusted HR for overall survival (OS) was 1.09 (95% CI: 0.68, 1.75). The ORR was 48.7% (95% CI 39.5, 58.1) in the JAYPIRCA arm and 38.7% (95% CI 29.9, 48.0) in the investigator choice arm.

Open at the source →